INT21604

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.73
First Reported 1983
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 13
Disease Relevance 9.50
Pain Relevance 0.79

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
B-cell 1
lymphocytes 1
BDNF-AS (Homo sapiens)
Pain Link Frequency Relevance Heat
methadone 15 96.24 Very High Very High Very High
methotrexate 18 96.16 Very High Very High Very High
tolerance 1 92.88 High High
Morphine 1 91.40 High High
Adalimumab 40 90.04 High High
rheumatoid arthritis 45 90.00 High High
cytokine 7 87.20 High High
Angina 1 75.76 Quite High
cocaine 2 73.16 Quite High
cINOD 2 40.88 Quite Low
Disease Link Frequency Relevance Heat
Hepatitis C Virus Infection 453 100.00 Very High Very High Very High
Disease 88 100.00 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 324 98.76 Very High Very High Very High
Systemic Lupus Erythematosus 241 97.72 Very High Very High Very High
Hyperlipidemia 1 95.28 Very High Very High Very High
Infection 178 93.80 High High
Hepatitis 18 92.84 High High
Sprains And Strains 6 92.60 High High
Rheumatoid Arthritis 45 90.00 High High
Meningitis 19 88.24 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In the case of human BDNF and antiBDNF, the transcripts could act as cis-antisense RNAs and generate siRNAs targeting one of the initial transcripts, as do the natural cis-siRNAs described for genes involved in salt tolerance in Arabidopsis thaliana [39].
Localization (case) of antiBDNF associated with tolerance
1) Confidence 0.73 Published 2007 Journal Genomics Section Body Doc Link PMC2568880 Disease Relevance 0 Pain Relevance 0.05
Presence of anti-HCV was associated with duration of intravenous drug use and frequency of needle sharing (p less than 0.003 and p = 0.02, respectively, by chi-square for trend).
Localization (Presence) of anti-HCV associated with hepatitis c virus infection
2) Confidence 0.52 Published 1990 Journal Scand. J. Infect. Dis. Section Abstract Doc Link 2178279 Disease Relevance 0.73 Pain Relevance 0.10
Relatively weak responses were also obtained by immune stimuli in the following decreasing order: anti-IgG, antigen, histamine-releasing lymphokine and then the complement fragments C5a-desArg and C3a.
Localization (releasing) of anti-IgG
3) Confidence 0.22 Published 1986 Journal Agents Actions Section Abstract Doc Link 2425576 Disease Relevance 0 Pain Relevance 0.09
Brief treatment of human peripheral blood lymphocytes with the potential anti-HIV compound aurintricarboxylic acid (ATA) prompts the selective release of already bound L-selectin-specific anti-Leu8 and anti-LAM1-1 antibodies from the cells.
Localization (release) of anti-LAM1 in lymphocytes associated with acquired immune deficiency syndrome or hiv infection
4) Confidence 0.09 Published 1993 Journal Mol. Immunol. Section Abstract Doc Link 7505884 Disease Relevance 0.10 Pain Relevance 0
Results showed a statistically significant reduction in anti-HCV prevalence in the early 1990s (shortly after the introduction of NEPs).
Localization (prevalence) of anti-HCV associated with hepatitis c virus infection
5) Confidence 0.08 Published 2006 Journal Harm Reduct J Section Body Doc Link PMC1569828 Disease Relevance 0.53 Pain Relevance 0.04
Thereafter, anti-HCV screening was performed on the ADVIA Centaur (initially Bayer, Canada, now Siemens, Canada) and anti-HCV reactive samples re-tested on the Abbott Architect (Abbott, Canada).
Localization (screening) of anti-HCV associated with hepatitis c virus infection
6) Confidence 0.06 Published 2010 Journal BMC Public Health Section Body Doc Link PMC2868820 Disease Relevance 1.65 Pain Relevance 0
Specimens reactive for anti-HCV were retested by the second or third generation Recombinant Immunoblot Assay (Chiron, Emeryville, California) until July 1999 to confirm EIA specificity.
Localization (specificity) of anti-HCV associated with hepatitis c virus infection
7) Confidence 0.06 Published 2010 Journal BMC Public Health Section Body Doc Link PMC2868820 Disease Relevance 2.04 Pain Relevance 0
Thereafter, anti-HCV screening was performed on the ADVIA Centaur (initially Bayer, Canada, now Siemens, Canada) and anti-HCV reactive samples re-tested on the Abbott Architect (Abbott, Canada).
Localization (screening) of anti-HCV associated with hepatitis c virus infection
8) Confidence 0.05 Published 2010 Journal BMC Public Health Section Body Doc Link PMC2868820 Disease Relevance 1.56 Pain Relevance 0
The presence of anti-nuclear and anti-dsDNA autoantibodies was not associated with any clinical event.


Localization (presence) of anti-dsDNA
9) Confidence 0.04 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526573 Disease Relevance 0.26 Pain Relevance 0.40
On the assumption that lipoproteins may act as auto-antigens by forming immune complexes, the presence of anti-LDL and anti-HDL2 activity was investigated in circulating immune complexes obtained by polyethylene glycol (PEG) precipitation from the sera of coronary patients and controls.
Localization (presence) of anti-LDL
10) Confidence 0.03 Published 1983 Journal Atherosclerosis Section Abstract Doc Link 6651914 Disease Relevance 0.41 Pain Relevance 0.08
Ts cells have a known effect of suppressing polyclonal B-cell expansion, the event which consecutively leads to lower anti-DNA autoantibody secretion.
Localization (secretion) of anti-DNA in B-cell
11) Confidence 0.03 Published 2010 Journal Autoimmune Diseases Section Body Doc Link PMC2989704 Disease Relevance 0.57 Pain Relevance 0.04
Both anti-ssDNA and anti-dsDNA are involved in disease development and have been eluted from the kidneys of both experimental murine models and SLE patients [17].
Localization (eluted) of anti-dsDNA associated with systemic lupus erythematosus and disease
12) Confidence 0.01 Published 2010 Journal Autoimmune Diseases Section Body Doc Link PMC2989704 Disease Relevance 1.16 Pain Relevance 0
In CSF, anti-nuclear, anti-dsDNA, anti-cardiolipin, and anti-?
Localization (anti-dsDNA) of anti-dsDNA
13) Confidence 0.00 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2556096 Disease Relevance 0.50 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox